Please login to the form below

Not currently logged in
Email:
Password:

FDA clears Advair follow up Breo for asthma

But respiratory drug given the thumbs up for adults only

GSK GlaxoSmithKline house 

GlaxoSmithKline (GSK) and Theravance have won US FDA approval for respiratory drug Breo for asthma in adults, but not in children.

The decision to limit use of the Breo (fluticasone furoate/vilanterol) to patients aged 18 years and older was expected after an FDA advisory committee voted in March not to recommend approval in younger patients. 

The reluctance stems from longstanding caution at the FDA about the safety of long-acting beta agonists and inhaled corticosteroids, so the approval of the combination in adults - after a five-year hiatus - is something of a step forward even with the exclusion of children from the label.  

The FDA has already asked GSK and Theravance to carry out additional studies to show its safety in the paediatric setting. Analysts have suggested that adults remain the largest market segment however, adding that approval in asthma should help Breo top the $1bn threshold by 2020.

Breo - a follow-up to GSK's big-selling Advair (fluticasone propionate/salmeterol) brand - has been approved as a once-daily therapy and is the second asthma drug to be approved in the US from GSK in the last year after Arnuity (fluticasone furoate) got the nod last August.

The green light in asthma comes two years after Breo was approved by the US regulator as a treatment for chronic obstructive pulmonary disease (COPD)

Breo and other new drugs such as Anoro (umeclidinium bromide/vilanterol) have been positioned as successors to Advair, which saw sales slip 15% to a little over £4.2bn ($6.35bn) last year  - although increasing competition and downward pricing pressure in the respiratory market has pegged back the growth of its respiratory franchise.

Analysts predict that GSK's new combination asthma and COPD drugs and those from competitors such as Novartis and Boehringer Ingelheim are more likely to sell in the $1bn-$2bn range, a step down from Advair's performance at peak.

With that in mind, GSK and Theravance have started developing a triple therapy - based on fluticasone, umeclidinium and vilanterol delivered via a single device - that they hope will show sufficient improvement over dual therapy rivals to set a new standard respiratory therapy.

Article by
Phil Taylor

5th May 2015

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Solaris Health

The beauty of detail: an effective, compelling medical communications campaign requires each component to be carefully planned, expertly crafted and...

Latest intelligence

Australian Flu and the dilemma of naming diseases
...
Wearables and Healthcare
What place do wearables have in affecting actual patient health outcomes and can they contribute to the NHS’s sustainability agenda? Or are they just the latest fad?...
What does a future-proof rep look like?
Businesses can no longer afford to push ahead with the traditional Key Account Management model....

Infographics